Filaggrin and beyond

Annals of Allergy Asthma & Immunology, Год журнала: 2023, Номер 132(2), С. 187 - 195

Опубликована: Сен. 25, 2023

Atopic dermatitis (AD) is the most common inflammatory skin disease worldwide, affecting 20% of children and 5% adults. One critical component in pathophysiology AD epidermal barrier, with its outermost layer, stratum corneum (SC), conferring biochemical properties that enable resilience against environmental threats maintain homeostasis. The barrier may be conceptualized as a key facilitator complex interactions between genetics, host immunity, cutaneous microbiome, exposures. genetic risk factor for development persistence loss-of-function mutation FLG, recent advances genomics focusing on rare variant discovery, establishment pathogenic mechanisms, exploration role other differentiation gene variants AD. Aberrant type 2 responses down-regulate transcription genes, alter composition SC lipids, induce further injury through neurocutaneous feedback loop itch-scratch cycle. dysbiotic epidermis exhibits reduced bacterial diversity enhanced colonization Staphylococcus Malassezia species, which contribute to both direct action toxins perpetuation cascades. Enhanced understanding each mechanisms underpinning disruption has led novel topical systemic molecules, including interleukin (IL)-4Ra, IL-13, PDE4, Janus-associated kinase inhibitors, whose clinical effectiveness exceeds conventional treatment modalities. In this narrative review, we aim summarize current above-mentioned pathophysiological therapeutic focus genetic, cellular, molecular development.

Язык: Английский

---

Skin Barrier in Atopic Dermatitis

Journal of Investigative Dermatology, Год журнала: 2024, Номер 144(5), С. 989 - 1000.e1

Опубликована: Апрель 19, 2024

Язык: Английский

---

Factors by which global warming worsens allergic disease

Annals of Allergy Asthma & Immunology, Год журнала: 2023, Номер 131(6), С. 694 - 702

Опубликована: Сен. 7, 2023

Язык: Английский

---

Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics

Clinical Reviews in Allergy & Immunology, Год журнала: 2024, Номер 66(3), С. 274 - 293

Опубликована: Июнь 28, 2024

Язык: Английский

---

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment

American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response AD are traditionally reported through clinical assessments including the Eczema Area Severity Index or Investigator's Global Assessment. These rating scales visual used in trials to denotate severity. Alternatively, biomarkers open potential further enhance diagnosis AD, assess status potentially enable tailored treatment options for patients. Biomarkers be classified according their use, presentation, underlying/endogenous molecular mechanisms. Specifically, interleukin (IL)-13, which has been shown key biomarker pathogenesis, prediction development monitor severity/response treatment. Treatment with tralokinumab, human monoclonal antibody binds directly to—and subsequently blocks signaling of—IL-13, reduce inflammation, re-balance microbiome, improve barrier patients AD. In this review, AD-related biomarkers, role IL-13 driving impact inhibition by tralokinumab on other discussed.

Язык: Английский

---

A layer-cake structure composite of carboxymethyl chitosan crosslinked intercalation of bentonite for antimicrobial and repair effects

Materials Today Communications, Год журнала: 2025, Номер unknown, С. 111652 - 111652

Опубликована: Янв. 1, 2025

Язык: Английский

---

Prediction of Skin Irritation by Noninvasive Bioengineering Methods

Опубликована: Янв. 1, 2025

Язык: Английский

---

Primary atopic disorders: inborn errors of immunity causing severe allergic disease

Current Opinion in Immunology, Год журнала: 2025, Номер 94, С. 102538 - 102538

Опубликована: Фев. 27, 2025

Allergic diseases, including asthma, allergic rhinitis, atopic dermatitis, and food allergies, are driven by dysregulated immune responses, often involving IgE-mediated mast cell basophil activation, Th2 inflammation, epithelial dysfunction. While environmental factors well-known contributors, the genetic components underpinning these conditions increasingly understood. Traditionally viewed as polygenic multifactorial disorders, diseases can also be caused single-gene defects affecting system skin barrier, leading to profoundly responses. These monogenic disorders collectively referred primary or PADs. To date, over 48 have been established cause This review highlights (i) significance of PADs, (ii) biological pathways involved in pathogenesis (iii) clinical strategies differentiate PADs from their much more common counterparts, (iv) diagnostic for

Язык: Английский

---

Efficacy and safety of BSZY cream for mild-to-moderate atopic facial dermatitis: protocol of a randomised, double-blind, controlled trial

BMJ Open, Год журнала: 2025, Номер 15(3), С. e087149 - e087149

Опубликована: Март 1, 2025

Introduction Limited by the specific location of atopic facial dermatitis, treatment options for dermatitis are limited. Our previous research confirms that BiShengZhiYan cream (BSZY cream) can reconstruct damaged skin barrier and strengthen repair ability skin. However, little evidence its efficacy safety is available. Methods analysis A protocol a randomised, double-blind, controlled trial BSZY designed patients with mild-to-moderate dermatitis. We will recruit 130 from Yueyang Hospital Integrated Traditional Chinese Western Medicine, Shanghai University Medicine. The participants be assigned to group (treatment group) or emulsion matrix (control randomly. intervention period 4 weeks, once daily in morning evening. primary outcome Scoring Atopic Dermatitis Scale. Clinical Dermatologist Evaluation Form, Patient Self-Assessment Questionnaire Safety Indicators evaluated as secondary outcomes. follow-up conducted at week 8±3 days. condition assessed clinical dermatologist 0±3 days, 2±3 days 4±3 Ethics dissemination has been approved Medicine’s ethics committee (No. 2023-024). All asked sign an informed consent compliance Declaration Helsinki. On completion trial, we plan disseminate results through peer-reviewed publications present findings relevant scientific conferences. Data provided on reasonable request under participant confidentiality data privacy regulations. Trial registration number NCT05792826 .

Язык: Английский

---

Selected traditional Chinese herbal medicines for the treatment of atopic dermatitis - research progress on the effect and mechanism of actions

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 26, 2025

Atopic dermatitis (AD) is a common chronic, recurrent, inflammatory skin disease characterized by pruritus, lichen-like changes and dry skin. Due to the complex pathogenesis of AD, its mechanism primarily associated with genetic, barrier dysfunction, environmental, immune factors. AD has been routinely treated glucocorticoids, antihistamines, local immunomodulators, biological agents, small molecules; however, side effects are significant, treatment efficacy limited. In recent years, traditional Chinese medicine (TCM) gradually widely used in AD. Many studies have shown that TCM mainly regulates cytokines, gut microbiota system. Therefore, it plays crucial role The atopic using targeting multiple pathways targets, demonstrates significant therapeutic effects. This paper reviews reports on (including prescription, single TCM, metabolites), which provides theoretical basis for certain It can alleviate treat various ways. We should base our differentiation syndrome differentiation. With help modern medicine, clinical treating be improved.

Язык: Английский

---